PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials

医学 卡铂 培美曲塞 贝伐单抗 内科学 肺癌 化疗 肿瘤科 胃肠病学 顺铂 外科
作者
Xiangjiao Meng,Yu Chen,Ligang Xing,Xinchao Liu,Kaikai Zhao,Liyang Jiang,Li Zhang,Caicun Zhou,Jinming Yu
出处
期刊:BMJ Open Respiratory Research [BMJ]
卷期号:9 (1): e001294-e001294 被引量:1
标识
DOI:10.1136/bmjresp-2022-001294
摘要

Background To date, none of randomised trials aim to compare the efficacy of programmed death 1 (PD-1) inhibitor plus chemotherapy and bevacizumab plus chemotherapy as first-line treatment for non-squamous non-small-cell lung cancer (NSCLC). This analysis pooled prospective data to compare the survival benefits of the two regimens for advanced NSCLC without targetable genetic mutations. Methods Data were pooled from three randomised phase III clinical trials: NCT03607539 , NCT03134872 and NCT02954172 . 466 patients received PD-1 inhibitor (200 mg) plus pemetrexed (500 mg/m²) and platinum (cisplatin 75 mg/m 2 or carboplatin area under the curve (AUC) 5 mg/mL/min), while 432 patients received bevacizumab (15 mg/kg) plus paclitaxel (175 mg/m 2 ) and carboplatin (AUC 6 mg/mL/min). Propensity score matching in a 1:1 ratio was performed to balance baseline characteristics of the two arms. The endpoints of this analysis were progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Results In total, 375 patients in each arm were matched. With a median follow-up of 23 months (IQR 21–26), results showed that median PFS was significantly prolonged in the PD-1 inhibitor arm than in the bevacizumab arm (10.1 vs 7.4 months; HR 0.62, 95% CI 0.52 to 0.73, p<0.001). Improved OS was also demonstrated in the PD-1 inhibitor arm (27.9 vs 20.2 months; HR 0.75 95% CI 0.61 to 0.91, p=0.004). ORR in the PD-1 inhibitor arm was 56.8%, while that in the bevacizumab arm was 45.1%. However, exploratory subgroup analysis indicated that median PFS and median OS of the two arms were comparable in patients with negative programmed death ligand 1 expression or in patients aged ≥65 years old. Conclusions PD-1 inhibitor plus chemotherapy was associated with significant survival benefits compared with bevacizumab plus chemotherapy in patients with advanced non-squamous NSCLC, which provides evidence support to guide clinical practice. Nonetheless, the comparative survival outcomes in several subgroups indicated that bevacizumab plus chemotherapy still mattered.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SaSa发布了新的文献求助10
1秒前
jialin发布了新的文献求助10
1秒前
美好芷波完成签到,获得积分10
2秒前
鲤鱼凝云完成签到,获得积分10
2秒前
垃圾完成签到,获得积分20
3秒前
SmuA发布了新的文献求助10
3秒前
8秒前
Tonnyjing应助耳朵儿歌采纳,获得10
9秒前
jialin完成签到,获得积分10
9秒前
10秒前
咖啡不加冰完成签到,获得积分10
10秒前
向晚发布了新的文献求助10
11秒前
希望天下0贩的0应助SmuA采纳,获得30
13秒前
赘婿应助帅比4采纳,获得10
13秒前
感动的一德完成签到,获得积分10
14秒前
16秒前
小萝卜完成签到,获得积分10
16秒前
davyean完成签到,获得积分10
17秒前
快乐小狗完成签到,获得积分10
17秒前
liuyingyun完成签到,获得积分10
18秒前
菜菜完成签到,获得积分20
19秒前
西瓜完成签到 ,获得积分10
19秒前
SSS完成签到 ,获得积分10
19秒前
21秒前
闪闪满天发布了新的文献求助10
21秒前
23秒前
bkagyin应助释然zc采纳,获得10
24秒前
水水完成签到 ,获得积分10
26秒前
祝君早日毕业完成签到,获得积分10
26秒前
26秒前
大肥羊发布了新的文献求助10
26秒前
开放的紫伊完成签到,获得积分10
27秒前
MT完成签到 ,获得积分10
27秒前
28秒前
28秒前
搜集达人应助身处人海采纳,获得10
28秒前
kuiuLinvk完成签到,获得积分10
28秒前
29秒前
发育不减肥完成签到,获得积分10
30秒前
zhangjingchang完成签到,获得积分10
30秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
【本贴是提醒信息,请勿应助】请在求助之前详细阅读求助说明!!!! 20000
Evolution 5000
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
La Chine révolutionnaire d'aujourd'hui / Van Min, Kang Hsin 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3044554
求助须知:如何正确求助?哪些是违规求助? 2701739
关于积分的说明 7384800
捐赠科研通 2345718
什么是DOI,文献DOI怎么找? 1241583
科研通“疑难数据库(出版商)”最低求助积分说明 603979
版权声明 595503